3 Overlooked Stocks Positioned for the Next Market Rotation

Summary

Tech has carried this market for years, but it isn't the only game left running. Small caps are outperforming in 2026, the Magnificent Seven have cooled, and money is starting to spread into corners of the market that retail investors rarely check. Healthcare, insurance and regional banking are all quietly building momentum before the crowd shows up. That's the setup Oxford Club Chief Income Strategist Marc Lichtenfeld is watching right now. His view: the sectors working today won't stay secret for long, and getting positioned early, before the next rotation becomes obvious, is where the real edge sits. Why Diversification Still Matters in a One-Sector MarketConcentration feels good on the way up. Artificial intelligence stocks have proven that this year, and it's tempting to let one winning trade become most of a portfolio. The problem shows up on the way down. Stocks take the stairs up, but the elevator down—and a sector that's been running hot for a while tends to fall hard and fast when it finally turns. Investors who got used to buying every dip often get caught waiting for a bounce that doesn't materialize as quickly as they expect. That's the trap concentration sets. It works until it doesn't, and by then it's often too late to rotate out cleanly. Lichtenfeld's point isn't to abandon technology. It's to make sure a portfolio has other legs to stand on when one leg gets wobbly, something already working quietly in sectors most retail investors haven't circled back to yet. Ligand Pharmaceuticals Turns Drug Risk Into Someone Else's ProblemHealthcare tends to hold up in any economy, recession or not, because people don't stop needing medicine. Within that sector, Ligand Pharmaceuticals NASDAQ: LGND stands out for a business model that looks more like a royalty company than a traditional biotech. Ligand Pharmaceuticals TodayLGNDLigand Pharmaceuticals$316.24 0.00 (0.00%) As of 07/10/2026 04:00 PM Eastern52-Week Range$120.68▼$326.63P/E Ratio42.91Price Target$292.86 ...